Home › Nierkanker (niercelcarcinoom) › Minnesota › Rochester
Nierkanker (niercelcarcinoom) klinische studies in Rochester, MN
14 studies voor Nierkanker (niercelcarcinoom) zoeken deelnemers op locaties in en rond Rochester (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruterenFase 1
- Mayo Clinic Rochester, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruterenFase 1
- Exelixis Clinical Site #68, Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruterenFase 2
- Mayo Clinic in Rochester, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruterenObservatieonderzoek
- Mayo Clinic Rochester, Rochester
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekruterenFase 2
- Mayo Clinic in Rochester, Rochester
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruterenFase 1/2
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruterenObservatieonderzoek
- Mayo Clinic (Rochester), Rochester
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruterenFase 1
- Xencor Investigative Site, Rochester
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekruterenFase 1/2
- Mayo Clinic, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruterenFase 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
RekruterenFase 2
- Mayo Clinic in Rochester, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RekruterenObservatieonderzoek
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruterenFase 1/2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekruterenFase 1/2
- Mayo Clinic in Minnesota, Rochester
Nierkanker (niercelcarcinoom) studies in andere steden
- Houston, TX35 studies
- New York City, NY27 studies
- Nashville, TN23 studies
- Dallas, TX23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Pittsburgh, PA15 studies
- Philadelphia, PA15 studies
- Queens, NY15 studies
- Jacksonville, FL14 studies
Andere studies in Rochester
- Borstkanker42 studies
- Niet-kleincellige longkanker37 studies
- Metastatische kanker31 studies
- Kanker (alle vormen)30 studies
- Eierstokkanker29 studies
- Colorectale kanker29 studies
- Multipel myeloom24 studies
- Hartfalen22 studies
- Prostaatkanker22 studies
- Aldermeesklierkanker22 studies
- Endometriumkanker20 studies
- Longkanker20 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.